Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bavarian Nordic A/S to present new evidence for mechanism of action for PROSTVAC immunotherapy at the 2014 ASCO Annual Meeting


Thursday, 15 May 2014 01:03am EDT 

Bavarian Nordic A/S:Says a paper featuring the company's cancer immunotherapy candidate PROSTVAC will be presented as a poster at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June 3.Says the presented work provides new evidence elucidating the mechanism of action of PROSTVAC immunotherapy for prostate cancer.Says patients administered PROSTVAC immunotherapy showed evidence of enhancement of PSA-specific T cell responses compared to subjects administered placebo viral vectors.Says increased numbers and improved quality of activated PSA-specific T cells were observed with the PROSTVAC prime and boost regimen compared to single vector regimens in preclinical models.Says that the authors conclude that PROSTVAC immunotherapy elicits broad, functional T cell immunity to PSA, which then expands to include immune responses against endogenous tumor antigens not targeted by the immunotherapy, via antigen spreading. 

Company Quote

318.0
4.0 +1.27%
4 May 2015